488 related articles for article (PubMed ID: 18368615)
1. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
Cruickshank CC; Montebello ME; Dyer KR; Quigley A; Blaszczyk J; Tomkins S; Shand D
Drug Alcohol Rev; 2008 May; 27(3):326-33. PubMed ID: 18368615
[TBL] [Abstract][Full Text] [Related]
2. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual.
McGregor C; Srisurapanont M; Mitchell A; Wickes W; White JM
J Subst Abuse Treat; 2008 Oct; 35(3):334-42. PubMed ID: 18329221
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence.
Longo M; Wickes W; Smout M; Harrison S; Cahill S; White JM
Addiction; 2010 Jan; 105(1):146-54. PubMed ID: 19839966
[TBL] [Abstract][Full Text] [Related]
4. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
[TBL] [Abstract][Full Text] [Related]
5. Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study.
Pahwa R; Lyons KE
Mov Disord; 2003 May; 18(5):584-7. PubMed ID: 12722174
[TBL] [Abstract][Full Text] [Related]
6. The effect of mirtazapine in patients with chronic pain and concomitant depression.
Freynhagen R; Muth-Selbach U; Lipfert P; Stevens MF; Zacharowski K; Tölle TR; von Giesen HJ
Curr Med Res Opin; 2006 Feb; 22(2):257-64. PubMed ID: 16466597
[TBL] [Abstract][Full Text] [Related]
7. An open-label study of mirtazapine as treatment for combat-related PTSD.
Alderman CP; Condon JT; Gilbert AL
Ann Pharmacother; 2009 Jul; 43(7):1220-6. PubMed ID: 19584388
[TBL] [Abstract][Full Text] [Related]
8. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.
Shearer J; Darke S; Rodgers C; Slade T; van Beek I; Lewis J; Brady D; McKetin R; Mattick RP; Wodak A
Addiction; 2009 Feb; 104(2):224-33. PubMed ID: 19149817
[TBL] [Abstract][Full Text] [Related]
10. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial.
Poyurovsky M; Pashinian A; Weizman R; Fuchs C; Weizman A
Biol Psychiatry; 2006 Jun; 59(11):1071-7. PubMed ID: 16497273
[TBL] [Abstract][Full Text] [Related]
11. Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study.
Varia I; Venkataraman S; Hellegers C; Gersing K; Doraiswamy PM
Psychopharmacol Bull; 2007; 40(1):47-56. PubMed ID: 17285095
[TBL] [Abstract][Full Text] [Related]
12. The nature, time course and severity of methamphetamine withdrawal.
McGregor C; Srisurapanont M; Jittiwutikarn J; Laobhripatr S; Wongtan T; White JM
Addiction; 2005 Sep; 100(9):1320-9. PubMed ID: 16128721
[TBL] [Abstract][Full Text] [Related]
13. The effect of mianserin add-on, on the intensity of opioid withdrawal symptoms during detoxification program--a randomized, double blind, placebo controlled, prospective study.
Herman I; Shamir D; Bar-Hamburger R; Pick CG; Schreiber S
Addict Behav; 2005 Jul; 30(6):1154-67. PubMed ID: 15925125
[TBL] [Abstract][Full Text] [Related]
14. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification.
Liappas J; Paparrigopoulos T; Tzavellas E; Rabavilas A
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):55-60. PubMed ID: 15610945
[TBL] [Abstract][Full Text] [Related]
15. Mirtazapine improves alcohol detoxification.
Liappas J; Paparrigopoulos T; Malitas P; Tzavellas E; Christodoulou G
J Psychopharmacol; 2004 Mar; 18(1):88-93. PubMed ID: 15107190
[TBL] [Abstract][Full Text] [Related]
16. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study.
Altintoprak AE; Zorlu N; Coskunol H; Akdeniz F; Kitapcioglu G
Hum Psychopharmacol; 2008 Jun; 23(4):313-9. PubMed ID: 18327889
[TBL] [Abstract][Full Text] [Related]
18. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine.
Honig A; Kuyper AM; Schene AH; van Melle JP; de Jonge P; Tulner DM; Schins A; Crijns HJ; Kuijpers PM; Vossen H; Lousberg R; Ormel J;
Psychosom Med; 2007; 69(7):606-13. PubMed ID: 17846258
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study.
Poyurovsky M; Epshtein S; Fuchs C; Schneidman M; Weizman R; Weizman A
J Clin Psychopharmacol; 2003 Jun; 23(3):305-8. PubMed ID: 12826992
[TBL] [Abstract][Full Text] [Related]
20. Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety.
Wålinder J; Prochazka J; Odén A; Sjödin I; Dahl ML; Ahlner J; Bengtsson F
Hum Psychopharmacol; 2006 Apr; 21(3):151-8. PubMed ID: 16444795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
